inhaled dual PI3K_,_ kinase inhibitor

Ph. II (3 mg QD) for asthma; withdrawn

from re-opt. of oral PI3K_ inhibitor

Journal of Medicinal Chemistry

AstraZeneca, Gothenburg, SE


7. The AstraZeneca inhaled dual PI3K_,_ inhibitor AZD8154 is long-acting in the lung but has low systemic exposure and is selective, potentially avoiding the known side effects of systemic…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: